OTTAWA, May 1 (Reuters) – The Canadian health regulator said on Friday that it had approved Canada-based Apotex’s generic version of semaglutide, making it the second copycat version of Danish drugmaker Novo Nordisk’s blockbuster diabetes drug Ozempic authorized in the country.
(Reporting by Ismail Shakil and Ryan Patrick Jones; Editing by Caitlin Webber)
Keyword: Text NEWS to 39327*
Details: Breaking News Alerts
Messages: expect up to 1 per week
Keyword: Text WEATHER to 39327*
Details: Daily Weather Forecast
Messages: expect up to 7 per week
Sponsor: King’s Campers
Keyword: Text TRAFFIC to 39327*
Details: Traffic and road alerts
Messages: expect up to 5 per week
*Message & data rates may apply. Text STOP to 39327 to quit. Text HELP for help or visit www.vibes.com/help/ for support. No purchase necessary. Marketing text messages generated by an automated dialer will be delivered to the phone number you provide at opt-in
Comments